B BioPulse
Clinical Trials Sep 28, 2026 · 1 min read · 3,750 views

Roche kidney drug's Phase 3 win sets up path to accelerated approval

A

Aiden Brooks

Editorial · Sep 28, 2026

Roche kidney drug's Phase 3 win sets up path to accelerated approval

Roche moves closer to entering an increasingly crowded kidney disease market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved drugs. The Swiss pharma reported interim Phase 3 results Wednesday

Read Original Source Back to Feed

← Previous

US trade officials hear case on declining German drug prices

Next →

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

Related Reading

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
Clinical Trials

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

Sep 27, 2026

Akeso details survival win for its PD-1xVEGF drug versus Keytruda
Clinical Trials

Akeso details survival win for its PD-1xVEGF drug versus Keytruda

Sep 27, 2026

Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials
Clinical Trials

Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials

Sep 26, 2026